Following a comprehensive review, the FDA found no increased risk of suicidal ideation or behavior with GLP-1 receptor agonist medications. The agency is requiring removal of SI/B warning language from the labels of Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide), which are approved for weight reduction. This updates a January 2024 safety communication and will align labeling across all FDA-approved GLP-1 RAs. Patients are advised to continue their medications and discuss concerns with their healthcare providers.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.